Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activityin vitroandin vivoagainst chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activityin vitroandin vivoagainst chronic lymphocytic leukemia

Published:2016-07-15 Issue:9 Volume:5 Page:e1211220
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Vyas Maulik,Schneider Ann-Charlott,Shatnyeva Olga,Reiners Katrin S.,Tawadros Samir,Kloess Stephan,Köhl Ulrike,Hallek Michael,Hansen Hinrich P.,Pogge von Strandmann Elke

Funder

José Carreras Leukämie-Stiftung

Deutsche Forschungsgemeinschaft

Deutsche Krebshilfe

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.1080/2162402X.2016.1211220

Reference50 articles.

1. DNA damage response and evasion from immunosurveillance in CLL: new options for NK cell-based immunotherapies

2. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies

3. Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy

4. Rituximab for the treatment of patients with chronic lymphocytic leukemia

5. Primary B-CLL Resistance to NK Cell Cytotoxicity can be Overcome In Vitro and In Vivo by Priming NK Cells and Monoclonal Antibody Therapy

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity;Cancer Immunology, Immunotherapy;2024-08-08

2. Trispecific antibodies for cancer immunotherapy;Immunology;2023-03-08

3. Emerging Therapies in CLL in the Era of Precision Medicine;Cancers;2023-03-03

4. When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy;Theranostics;2023

5. Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges;Frontiers in Oncology;2022-02-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3